000 03402cam a2200337 a 4500
003 EG-GiCUC
005 20250223032650.0
008 210102s2020 ua d f m 000 0 eng d
040 _aEG-GiCUC
_beng
_cEG-GiCUC
041 0 _aeng
049 _aDeposite
097 _aPh.D
099 _aCai01.08.08.Ph.D.2020.Sa.P
100 0 _aSami Mohamed Awadalla Mohamed
245 1 2 _aA pharmaceutical study on an osmotic controlled delivery of a poor water soluble drug /
_cSami Mohamed Awadalla Mohamed ; Supervised Magdy Ibrahim Mohamed , Abdulaziz Mohsen Almahallawi
246 1 5 _aدراسة صيدلانية على توصيل أوزموزى محكم لعقار ضعيف الذوبان فى الماء
260 _aCairo :
_bSami Mohamed Awadalla Mohamed ,
_c2020
300 _a125 P. :
_bcharts , facimiles ;
_c25cm
502 _aThesis (Ph.D.) - Cairo University - Faculty of Pharmacy - Department of Pharmaceutics
520 _aDiacerine (DCN) is an anti-osteoarthritic drug with low bioavailability.In an attempt to overcome this drawback,thirty nine ternary solid dispersion formulae were designed by ordinary fusion method using carrier polymers such as either Pluronic® F127(PF127), Solutol®HS15 or Polyethylene Glycol 35K (PEG 35K)with different weight ratio and constant weight of drug. They were optimizedby face-centered central composite statistical design and evaluated for the saturated solubility, initial dissolution rate in 5minutes (IDR5min) and cumulative drug release at 40 and 60 minutes(Q40min, Q60min respectively) as responses. Then rotatable central composite design was conducted to optimize the release profile of osmotic pump tablets that contained optimum DCN solid dispersion. Furthermore the in-vivo performance of the optimized osmotic formula was assessed on healthy rabbits.The optimized solid dispersion formula was DCN:PF127:Solutol®HS 15 with ratio 1:1:1; that showed the significant improvement in the initial dissolution rate with approximately4.86±0.95æg % / min of the drug released in the first 5 min, 67.635±3.1 %, 80.28±4.5 % at Q40min and Q60minrespectively. Furthermore the saturated solubility of optimized DCN solid dispersion;was 62.91±4.8 æg/ml; more than pure DCN which corresponds to a 5.9 fold difference.On optimization of asymmetric osmotic pump tablets, it was found that the drug release was inversely proportional to coat concentration of the membrane and concentration of gelling polymer, while it was directly proportional to the amount of osmogen. The optimized formula had the following parameters; coat concentration (Opadry® CA) was 3%w/v, gelling polymer (HPMC E15) was 1%w/w and osmogen concentration (NaCl) was 35.8%w/w. The results also displayed the reliability of this system to control the release of drug at zero order kinetic for up to 24 hours. The in vivo studies conducted on rabbits revealed a significant enhancing in bioavailability of the optimized osmotic pump (28.84±3.32 ng.hr/ml) compared to pure DCN (10.39±1.45 ng.hr/ml)
530 _aIssued also as CD
653 4 _aBioavailability
653 4 _aDiacerine
653 4 _aTernary solid dispersion
700 0 _aAbdulaziz Mohsen Almahallawi ,
_eSupervisor
700 0 _aMagdy Ibrahim Mohamed ,
_eSupervisor
856 _uhttp://172.23.153.220/th.pdf
905 _aNazla
_eRevisor
905 _aShimaa
_eCataloger
942 _2ddc
_cTH
999 _c79409
_d79409